Home › Companies › Regeneron Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Regeneron Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Regeneron Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Regeneron Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Joseph L. Goldstein, M.D. | 72,398,297 | 30,904,254 | 170,603 | -- | 5,543,411 | Majority: yes |
| Elect Director: Christine A. Poon | 79,409,070 | 24,004,880 | 59,204 | -- | 5,543,411 | Majority: yes |
| Elect Director: David P. Schenkein, M.D. | 99,241,219 | 4,180,107 | 51,828 | -- | 5,543,411 | Majority: yes |
| Elect Director: Craig B. Thompson, M.D. | 81,933,651 | 21,378,567 | 160,936 | -- | 5,543,411 | Majority: yes |
| Elect Director: Huda Y. Zoghbi, M.D. | 100,665,234 | 2,698,397 | 109,523 | -- | 5,543,411 | Majority: yes |
| Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, | 102,503,788 | 6,443,958 | 68,819 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 24, 2026 was ap | 96,469,374 | 6,898,268 | 105,512 | -- | 5,543,411 | Majority: yes |
Source: Regeneron Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-17 — read the filing on EDGAR.
Each item below shows how the 1,058 asset managers that disclosed a Regeneron Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Regeneron Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-06-12.
Combines 26 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on ”): 96,469,374 for, 6,898,268 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 93% for, 7% against (99.3% of the company cast a for/against vote).
The 1,044 asset managers below cast 93% of the shares they voted on this item FOR (87,145,165 for, 6,913,415 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,124,454 | 87 | 1 | 0 | For |
| Invesco | 7,942,428 | 0 | 0 | 0 | For |
| BlackRock | 7,730,573 | 6 | 0 | 0 | For |
| Dodge & Cox | 7,627,881 | 0 | 0 | 0 | For |
| Fidelity | 4,672,312 | 0 | 0 | 0 | For |
| Putnam | 3,902,522 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,093,290 | 0 | 0 | 0 | For |
| State Street | 2,992,913 | 33,716 | 0 | 0 | For |
| Capital Group | 4,045 | 2,724,305 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 2,612,941 | 0 | 0 | 0 | For |
| JPMorgan | 2,207,520 | 0 | 0 | 0 | For |
| Loomis Sayles | 2,115,613 | 62,432 | 0 | 0 | For |
| Nuveen | 2,119,663 | 706 | 0 | 0 | For |
| Wellington | 2,008,083 | 0 | 0 | 0 | For |
| TIAA | 1,818,255 | 0 | 0 | 0 | For |
| Charles Schwab | 1,627,852 | 0 | 0 | 0 | For |
| Amundi | 0 | 985,490 | 0 | 0 | Against |
| Northern Trust | 824,785 | 7,810 | 0 | 0 | For |
| American Century | 761,558 | 58,225 | 0 | 0 | For |
| AQR | 806,915 | 0 | 0 | 0 | For |
| Goldman Sachs | 577,782 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 538,915 | 0 | 0 | 0 | For |
| Neuberger Berman | 513,408 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 458,093 | 2,374 | 0 | 0 | For |
| Two Sigma | 445,565 | 0 | 0 | 0 | For |
Showing the 25 largest of 1,044 asset managers. See all 1,044 in the interactive database.
Meeting held 2026-06-12.
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm”): 102,503,788 for, 6,443,958 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 99% for, 6% against (100% of the company cast a for/against vote).
The 183 asset managers below cast 99.7% of the shares they voted on this item FOR (39,806,087 for, 100,438 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,078,691 | 9,392 | 0 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,288,926 | 573 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 1,276,358 | 18 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 361,859 | 0 | 0 | 0 | For |
| First Trust | 361,685 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 158,409 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| Brighthouse | 143,934 | 63 | 11,210 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 147,894 | 0 | 0 | 0 | For |
Showing the 25 largest of 183 asset managers. See all 183 in the interactive database.
Meeting held 2026-06-12.
Combines 7 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joseph L. Goldstein, M.D.”): 72,398,297 for, 30,904,254 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 70% for, 30% against (99.3% of the company cast a for/against vote).
The 180 asset managers below cast 78% of the shares they voted on this item FOR (31,057,875 for, 8,803,065 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,063,926 | 24,154 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,285,929 | 3,570 | 0 | 0 | For |
| Fidelity | 1,000,108 | 2,267,071 | 0 | 0 | Against |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,816,925 | 0 | 0 | Against |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 2,648 | 1,273,728 | 0 | 0 | Against |
| T. Rowe Price | 871,316 | 361 | 0 | 0 | For |
| Charles Schwab | 788,351 | 262 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 0 | 361,859 | 0 | 0 | Against |
| First Trust | 0 | 361,685 | 0 | 0 | Against |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 0 | 268,093 | 0 | 0 | Against |
| Jackson National | 105,912 | 147,059 | 0 | 0 | Against |
| Prudential/PGIM | 176,021 | 1,777 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 158,409 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| Brighthouse | 125,794 | 18,203 | 11,210 | 0 | For |
| ProShares | 0 | 151,342 | 0 | 0 | Against |
| Equitable | 101,000 | 46,894 | 0 | 0 | For |
Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.
Meeting held 2026-06-12.
Combines 6 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christine A. Poon”): 79,409,070 for, 24,004,880 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 76% for, 23% against (99.4% of the company cast a for/against vote).
The 180 asset managers below cast 86% of the shares they voted on this item FOR (34,098,119 for, 5,762,822 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,087,750 | 331 | 0 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,287,026 | 2,473 | 0 | 0 | For |
| Fidelity | 3,236,665 | 30,514 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,816,925 | 0 | 0 | Against |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 2,648 | 1,273,728 | 0 | 0 | Against |
| T. Rowe Price | 871,316 | 361 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 0 | 361,859 | 0 | 0 | Against |
| First Trust | 0 | 361,685 | 0 | 0 | Against |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 0 | 268,093 | 0 | 0 | Against |
| Jackson National | 249,121 | 3,850 | 0 | 0 | For |
| Prudential/PGIM | 176,021 | 1,777 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 158,409 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| Brighthouse | 126,812 | 17,185 | 11,210 | 0 | For |
| ProShares | 0 | 151,342 | 0 | 0 | Against |
| Equitable | 147,894 | 0 | 0 | 0 | For |
Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.
Meeting held 2026-06-12.
Combines 7 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 99,241,219 for, 4,180,107 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 95% for, 4% against (99.4% of the company cast a for/against vote).
The 180 asset managers below cast 99.3% of the shares they voted on this item FOR (39,595,906 for, 264,142 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,088,034 | 50 | 0 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,289,499 | 0 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 1,276,376 | 0 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 361,859 | 0 | 0 | 0 | For |
| First Trust | 361,685 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 158,409 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| Brighthouse | 143,042 | 955 | 11,210 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 101,000 | 46,894 | 0 | 0 | For |
Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.
Meeting held 2026-06-12.
Combines 7 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Craig B. Thompson, M.D.”): 81,933,651 for, 21,378,567 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 79% for, 21% against (99.3% of the company cast a for/against vote).
The 180 asset managers below cast 86% of the shares they voted on this item FOR (34,147,289 for, 5,713,650 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,087,780 | 299 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,287,026 | 2,473 | 0 | 0 | For |
| Fidelity | 3,236,665 | 30,514 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,816,925 | 0 | 0 | Against |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 2,648 | 1,273,728 | 0 | 0 | Against |
| T. Rowe Price | 871,316 | 361 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 0 | 361,859 | 0 | 0 | Against |
| First Trust | 0 | 361,685 | 0 | 0 | Against |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 0 | 268,093 | 0 | 0 | Against |
| Jackson National | 249,121 | 3,850 | 0 | 0 | For |
| Prudential/PGIM | 176,021 | 1,777 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 158,409 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| Brighthouse | 125,857 | 18,140 | 11,210 | 0 | For |
| ProShares | 0 | 151,342 | 0 | 0 | Against |
| Equitable | 101,000 | 46,894 | 0 | 0 | For |
Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.
Meeting held 2026-06-12.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Huda Y. Zoghbi, M.D.”): 100,665,234 for, 2,698,397 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 104,000,000 outstanding shares: 97% for, 3% against (99.3% of the company cast a for/against vote).
The 180 asset managers below cast 99.2% of the shares they voted on this item FOR (39,571,211 for, 289,732 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,088,046 | 37 | 1 | 0 | For |
| Invesco | 3,728,116 | 0 | 0 | 0 | For |
| Dodge & Cox | 3,411,656 | 0 | 0 | 0 | For |
| BlackRock | 3,289,499 | 0 | 0 | 0 | For |
| Fidelity | 3,267,179 | 0 | 0 | 0 | For |
| JPMorgan | 2,153,087 | 0 | 0 | 0 | For |
| TIAA | 1,816,925 | 0 | 0 | 0 | For |
| Putnam | 1,533,988 | 0 | 0 | 0 | For |
| Capital Group | 1,278,632 | 0 | 0 | 0 | For |
| State Street | 1,276,376 | 0 | 0 | 0 | For |
| T. Rowe Price | 871,677 | 0 | 0 | 0 | For |
| Charles Schwab | 788,613 | 0 | 0 | 0 | For |
| Loomis Sayles | 511,945 | 0 | 0 | 0 | For |
| American Century | 361,859 | 0 | 0 | 0 | For |
| First Trust | 361,685 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 355,797 | 0 | 0 | 0 | For |
| Dimensional | 268,093 | 0 | 0 | 0 | For |
| Jackson National | 252,971 | 0 | 0 | 0 | For |
| Prudential/PGIM | 177,798 | 0 | 0 | 0 | For |
| Federated Hermes | 177,248 | 0 | 0 | 0 | For |
| WisdomTree | 158,409 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 156,099 | 0 | 0 | 0 | For |
| Brighthouse | 143,042 | 955 | 11,210 | 0 | For |
| ProShares | 151,342 | 0 | 0 | 0 | For |
| Equitable | 101,000 | 46,894 | 0 | 0 | For |
Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.
Meeting held 2025-06-13 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
99% fund support · no official result
The 6 asset managers below cast 99% of the shares they voted on this item FOR (41,753 for, 526 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GLENMEDE FUND INC | 24,176 | 0 | 0 | 0 | For |
| Slow Capital, Inc. | 9,904 | 0 | 0 | 0 | For |
| Investment Management Corp of Ontario | 5,649 | 0 | 0 | 0 | For |
| IMA Advisory Services, Inc. | 2,020 | 0 | 0 | 0 | For |
| PENSIOENFONDS RAIL & OV | 0 | 526 | 0 | 0 | Against |
| OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC | 4 | 0 | 0 | 0 | For |
Reported under meeting date 2026-04-14; no official results on file for that date.
11% fund support · no official result
The 3 asset managers below cast 11% of the shares they voted on this item FOR (1,207 for, 10,107 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0 | 10,107 | 0 | 0 | Against |
| Spinnaker ETF Series | 854 | 0 | 0 | 0 | For |
| Robertson Stephens Wealth Management, LLC | 353 | 0 | 0 | 0 | For |
Meeting held 2026-06-12.
All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TEALWOOD ASSET MANAGEMENT INC | 1,454 | 0 | 0 | 0 | For |
| McGowan Group Asset Management, Inc. | 83 | 0 | 0 | 0 | For |
Ranked by the number of Regeneron Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 104,000,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.70% |
| 2 | Invesco | 7.64% |
| 3 | BlackRock | 7.43% |
| 4 | Dodge & Cox | 7.33% |
| 5 | Fidelity | 4.49% |
| 6 | Putnam | 3.75% |
| 7 | T. Rowe Price | 2.97% |
| 8 | State Street | 2.91% |
| 9 | Capital Group | 2.62% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 8.60% | 13F |
| State Street | 4.49% | 13F |
| JPMorgan Chase | 4.15% | 13F |
| Franklin Templeton | 2.62% | 13F |
| T. Rowe Price | 2.09% | 13F |
| Wellington Management | 1.77% | 13F |
| Invesco | 1.66% | 13F |
| FMR (Fidelity) | 1.46% | 13F |
Percentages above are of 104,000,000 shares outstanding, as reported by Regeneron Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Regeneron Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Regeneron Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-12, in the 2025-2026 proxy season, 1,058 asset managers reported how they voted in their SEC Form N-PX filings, covering 9,052 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Proposal to approve, on an advisory basis, compensation of the Named Executive Officers. — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Regeneron Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-17.
Regeneron Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).